1. Introduction
===============

High blood pressure is one of the most common diseases in the world, which had affected nearly 1 billion of the adult population in 2000, and it is predicted that this proportion will increase to 29% (1.56 billion) by 2025 \[[@B001], [@B002]\]. Hypertension carries a high-risk factor for arteriosclerosis, myocardial infarction, end-stage renal disease and various ocular disorders \[[@B003]\]. In recent years, various epidemiological studies have indicated that hypertension plays an important role in the development of cataracts, but the mode of cataractogenesis is unclear \[[@B004]-[@B007]\]. Hypertension has profound effects, such as hypertensive retinopathy, hypertensive choroidopathy and hypertensive optic neuropathy, on the structure and function of the eye \[[@B008]\]. Apart from this, hypertension is thought to cause elevations of inflammatory cytokines, such as tumor necrosis factor-alpha, interleukin-6 and C-reactive protein, which are closely related to cataract formation through intense systemic inflammation \[[@B009], [@B010]\]. Lee *et al* reported that hypertension could induce conformational structure alteration of proteins in lens capsules, thereby exacerbating cataract formation \[[@B011]\]. Although several plausible mechanisms have been proposed based on laboratory results, the conclusions from epidemiologic studies remain inconsistent.

Although extensive studies have been performed to investigate the effects of fructose-induced hypertension on various organs \[[@B012], [@B013]\], data on lens integrity and its composition in a rat model are lacking. Several previous studies postulated that administration of cinnamaldehyde (CA) would improve oxidative stress, lipid abnormalities and inflammatory markers in the liver and the muscles of a fructose-fed rat \[[@B014]-[@B016]\]. Evidence from epidemiological *in vitro* and animal studies supports the idea that CA may reduce the cataractogenic effect in a hypertensive state.

CA is a naturally-occurring, organic compound that has a wide range of biological activities, such as anti-bacterial \[[@B017]\], anti-inflammatory \[[@B018]\], immunomodulatory \[[@B019]\], anti-diabetic \[[@B020]\], and aldose reductase inhibition activities \[[@B021]\]. Aldose reductase is well known to be a key enzyme in the polyol pathway which may be accelerated in fructose-induced hypertension leading to alterations in the morphology of the lens and its function. Hence, the objective of the present study was to explore the effects of different doses of CA on hypertension and on the levels of various biochemical parameters of the lens and serum in albino rats fed with a high-fructose diet.

2. Materials and Methods
========================

CA and fructose were purchased from Himedia Laboratories Ltd., Mumbai (India). Ramipril was obtained as a gift sample from Cipla Ltd. (Mumbai, India). All chemicals and reagents that were used were of analytical grade. Sprague-Dawley albino male rats (150 − 180 g) were used for the present study. They were housed in standard polypropylene cages (three rats per cage) and kept in a lightdark cycle of equal durations (12:12 hours) under constant environmental conditions (22 ± 2°C with 55% ± 5% humidity) according to the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. The rats were fed commercially-available normal pellet diet and water ad libitum under hygienic conditions. The experimental protocol was approved by the Institutional Animals Ethics Committee (IAEC, 994/GO/ERe/S/06/CPCSEA) of the SLT Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India.

Animals were randomly selected and divided into six groups, with six animals per group. Group 1 (normal) received a suspension of 0.5% carboxy methyl cellulose (10 mL/kg/day, p.o.) for six weeks. Groups 2 to 6 received a 10% (w/v) fructose solution in their drinking water (equivalent to a diet containing 48% − 57% fructose) for six weeks to induce hypertension \[[@B022]\]. By the end of the third week, hypertension had been induced in all animals in Groups 2 − 6. After induction of hypertension, from the beginning of week four until the end of week six, Group 2 (control) continued to receive 10% (w/v) fructose only, Group 3 (standard) received ramipril (1 mg/kg/day, p.o.), as well as 10% (w/v) fructose, and Groups 4 to 6 received CA at three different dose levels (20, 30 and 40 mg/kg/day, p.o.) respectively, as well as 10% (w/v) fructose. Blood pressure (systolic and diastolic) was monitored weekly by using a non-invasive blood pressure apparatus NIBP (CODA-08 Channel, Kent scientific, USA). Various pathophysiological parameters of the cataractogenic effects were evaluated after completion of the experimental protocol (six weeks). Blood samples from animals were collected by cardiac puncture, and serum was separated and stored at 2 − 8°C for further analysis of biochemical parameters.

After the completion of the experimental protocol, animals were sacrificed and their eyeballs were removed. Both lenses were separated from the eye balls and kept on graph paper. Their opacities were measured by using the photographic method. The graph lines would appear clearly in the transparent lens and cloudy or not visible in the cataractous lens. Then, the lenses were rapidly desiccated, washed with saline and carefully dried over fine filter paper, weighed and placed in clean, sterilized vials, and stored at -20°C until analysis. A lens homogenate was prepared from both lenses of each animal in 10 volumes of 0.1-M phosphate buffer, pH 7. The homogenate was centrifuged at 10,000 rpm for 1 hour, and the supernatant was separated and used for biochemical assays \[[@B023]\].

The supernatant from the lens and serum were used for the biochemical analysis. Enzymatic antioxidants were measured: The glutathione peroxidase (GPx) activity was measured by using the procedure of Tappel \[[@B024]\], and the enzyme activity of catalase (CAT) was measured spectrophotometrically at 240 nm by following the decomposition of H~2~O~2~ \[[@B025]\]. Superoxide dismutase (SOD) activity was determined by the addition of NADH (nicotinamide adenine dinucleotide) after incubation at 30°C for 1 minute, after which the reaction was stopped by the addition of 1.0 mL of glacial acetic acid into lens homogenate and the absorbance was measured at 560 nm \[[@B026]\]. The estimate of the non-enzymatic anti-oxidant reduced glutathione (GSH) was based on the reaction of Ellman's reagent \[[@B027]\]. Malondialdehyde (MDA) in the lens homogenate and serum was estimated by using the colorimetric methods of Ohkawa *et al* \[[@B028]\]. Total protein (TP) in the lens homogenate was assayed by using an ultraviolet (UV)-visible spectrophotometer at 610 nm and the method of Lowry *et al*. The protein content was calculated from a standard curve prepared with bovine serum albumin and expressed as μg/mg lens tissue \[[@B029]\]. The activity of Ca^2+^adenosine triphosphate (ATP)ase in the lens sample was measured by using the method of Rorive and Kleinzeller \[[@B030]\].

The data obtained were expressed as means ± standard errors of the mean (SEMs). The significance of the differences in mean values between multiple groups was analyzed by using the one-way analysis of variance (ANOVA) followed by the Newman-Keuls post test and the two-way ANOVA followed by Bonferroni's test. The level of statistical significance was set at *P* \< 0.05. Statistical analyses were performed using Graph Pad Prism 5.0 software.

3. Results
==========

Fructose-fed rats (Groups 2 -- 6) showed significant (*P* \< 0.001) development of hypertension in terms of systolic blood pressure (SBP) and diastolic blood pressure (DBP) within three weeks compared to day zero. The administration of ramipril in Group 3 (standard) at 1 mg/kg/day p.o. for 3 weeks and the administration of CA in Groups 4, 5, 6 at 20, 30, and 40 mg/kg/day p.o., respectively, for 3 weeks significantly (*P* \< 0.001) reduced the values of the blood pressure compared to those at the end of the third week (Fig. [1](#F001){ref-type="fig"}).

After the completion of the experimental protocol, the lenses of the eyes of the rats in all groups were removed and examined. The lenses of the eyes of the rats that had received the 10% (w/v) fructose solution (Groups 2 -- 6) were opaque (Fig. [2](#F002){ref-type="fig"})B - 2F) as compared to the normal groups (Fig. [2A](#F002){ref-type="fig"}). Treatments of rats with ramipril at 1 mg/ kg/day, p.o., as well as with CA at 20, 30, and 40 mg/kg/day, p.o., seemed to retard the progression of lens opacification (Fig. [2C - 2F](#F002){ref-type="fig"}) as compared to the control group (Fig. [2B](#F002){ref-type="fig"}). At doses of 30 and 40 mg/kg/day, CA had a very significant effect as lenses were more transparent than they were at a 20 mg/kg/day dose of CA.

Fructose administration significantly (*P* \< 0.001) decreased the level of enzymatic anti-oxidants (GPx, CAT, SOD) and non-enzymatic anti-oxidant GSH and increased the level of MDA in the serum of control group when compared to the normal group. Treatment with CA at 20, 30 and 40 mg/kg/day, p.o. and with ramipril at 1 mg/kg/day, p.o. simultaneously with fructose caused a significant (*P* \< 0.001) increase in the enzymatic antioxidants. The level of the non-enzymatic antioxidant GSH increased at in the rats treated with ramipril at 1 mg/kg/day (*P* \< 0.05) and with CA at 20, 30 and 40 mg/kg/day (*P* \< 0.05, *P* \< 0.01 and *P* \< 0.001, respectively). Ramipril and CA at all doses significantly (*P* \< 0.001) protected the test groups from lipid peroxidation, as indicated by a reduction in the level of MDA as compared to the control group (Table [1](#T001){ref-type="table"}).

Treatment with fructose in control group led to significant (*P* \< 0.001) decreases in the levels of enzymatic antioxidants (GPx, CAT, SOD) and in the level of the non-enzymatic antioxidant GSH (*P* \< 0.01), but to an increase in the level of MDA (*P* \< 0.001) in the lens, as compared to the levels in the normal group. The significant restoration of such antioxidants, GPx (*P* \< 0.001, *P* \< 0.001), CAT (*P* \< 0.001, *P* \< 0.001), SOD (*P* \< 0.001, *P* \< 0.001), and GSH (*P* \< 0.05, *P* \< 0.01) and MDA (*P* \< 0.001, *P* \< 0.001) level was observed in CA-treated group at 30 and 40 mg/kg/day respectively. Whereas, ramipril and CA (20 mg/kg/day) treated group showed significant restoration of GPx (*P* \< 0.001, *P* \< 0.001), CAT (*P* \< 0.01, *P* \< 0.01), SOD (*P* \< 0.001, *P* \< 0.05) and MDA (*P* \< 0.001, *P* \< 0.001) level respectively, and failed to significant restoration of GSH level as compared to the control group (Table [2](#T002){ref-type="table"}).

Significant (*P* \< 0.001) decreases in the levels of total protein and Ca^2+^ATPase were observed in the eye lenses of the animals in the control group, as compared to the normal group. Treatment with CA at the doses 30 and 40 mg/kg, along with fructose, caused significant increases in the total protein (*P* \< 0.05, *P* \< 0.001) and Ca^2+^ATPase activity (*P* \< 0.001, *P* \< 0.001) in the lens, while CA at 20 mg/kg, showed non-significant effects on total protein and Ca^2+^ATPase activity, as compared to the control group. Moreover, standard group significantly (*P* \< 0.001) increased the total protein only (Table [3](#T003){ref-type="table"}).

4. Discussion
=============

Some experimental and clinical evidence has identified enhanced oxidative stress as an important responsible factor for hypertension \[[@B031]\] while other epidemiological studies have speculated that oxidative stress is increased in hypertensive subjects \[[@B032]\]. However, whether enhanced oxidative stress is primary or secondary to the pathogenicity in hypertension has never been clearly established. In hypertension, the mechanisms responsible for oxidative stress are still not well understood, even though a decrease in the disposal of anti-oxidant mechanisms has been proposed.

Recent studies indicate that a high fructose diet is associated with high blood pressure \[[@B033], [@B034]\]. Various studies have shown that the excessive provision of fructose enhances the rate of production of reactive oxygen species in mitochondria, which may be responsible for oxidative damage to cellular constituents that results in several dysfunctions, namely, diminished anti-oxidant defense mechanism \[[@B035]\], decreased enzymatic and non-enzymatic anti-oxidants \[[@B036]\], metabolic syndrome with hyperlipidemia, insulin resistance \[[@B037]\], production of high non-enzymatic glycosylation \[[@B038]\] and formation of advanced glycation end products (AGEs) formation \[[@B039]\], which further leads to hypertension. This is reflected in our study. We found that 10% (w/v) fructose in drinking water for six weeks significantly raised the SBP and the DBP from the third week to the sixth week and augmented the systemic oxidative stress *via* depletion of serum antioxidants, including GPx, CAT, SOD, and GSH, and enhancement of the serum MDA level in the control group. On the other hand, similar to treatment with ramipril (1 mg/kg, p.o.), treatment with CA at three doses levels (20, 30 and 40 mg/kg, p.o.) significantly decreased the SBP and the DBP and restored the levels of serum antioxidants and MDA, suggesting that fructose-induced hypertension is strongly associated with oxidative stress.

Further, various epidemiological studies indicate that hypertension plays an important role in the development of cataracts \[[@B005], [@B007]\]. According to various experimental and clinical studies, impaired hypertension induces a conformational structural alteration of proteins in lens capsules \[[@B011]\], oxidative stress in the eye \[[@B040]\], activation of the polyol pathway of the glucose metabolism and formation of AGEs in the lens \[[@B041]\].

Enhanced oxidative stress in the lenses is a key mechanism of cataract formation. In the present study, fructose- fed animals (control group) showed marked cataractogenic effects through depletion of antioxidants, such as GPx, CAT, SOD, and GSH, and increased MDA level in the lens as compared to the animals in the normal group. Treatments with CA and with the standard antihypertensive drug ramipril (ACE inhibitor) concurrent with fructose solution showed significant protection against cataractogenesis *via* reduction of oxidative stress in the lenses of the eye. Both CA and ramipril significantly increased the levels of GPx, CAT, SOD, and GSH in the lens and decreased the level of MDA. That antioxidants play an important role in protection against cellular damage is well know: GPx decreases the levels of H~2~O~2~ in cells \[[@B042]\], and SOD is a chain-breaking anti-oxidant that converts superoxide to H~2~O~2~ and scavenges the superoxide anion to form hydrogen peroxide. CAT helps to keep the level of free radicals below toxic levels \[[@B043]\]. GSH is synthesized in the lens and is responsible for protecting the thiol groups on the proteins in the lens, thereby preventing the cross-linkage of lens crystalline. A reduced level of GSH is expected to cause the formation of disulphide bonds through sulfhydryl oxidation of lens crystalline which leads to cataractogenesis \[[@B044]\], while MDA is a product of membrane lipid peroxidation and decreases the content of water-soluble proteins. MDA protects against aggregation and insolubilization of proteins in the lens, and an increased level of MDA may be linked mainly or secondarily to a reduction in the content of antioxidants in the lens. MDA is known to play a role in lens opacification and can form cross-links between membrane lipids and proteins \[[@B045]\].

The transparency of the lens depends highly on the total content, order and structural integrity of the proteins in the lens. Relatively small changes, such as decrease the level of total protein and the Ca^2+^ATPase activity, may lead to the development of lenticular opacification and later cataracts. However, Ca^2+^ATPase is a major factor involved in maintaining homeostasis of lenticular Ca^2+^ levels, which counteracts the inward passive diffusion of Ca^2+^. In the present study, CA at 30- and 40-mg/kg dose levels significantly eliminated the cataractogenic effect *via* elevations of the total protein content and the Ca^2+^ATPase activity in the lens. The reduction in the total protein content in the lens might be due to the loss of Ca^2+^ATPase activity, which results in enhanced Ca^2+^ levels and leads to the formation of insoluble protein aggregates, the development of opacification, and ultimately cataractogenesis \[[@B046], [@B047]\].

Aldose reductase is the key enzyme in the polyol pathway that is accelerated in cataracts and elicits accumulation of polyol in the lens' cells. Its poor penetration through cellular membranes leads to osmotic swelling, changes in membrane permeability, leakage of GSH, and perhaps even the production of free radicals and hydrogen peroxide, causing generation of osmotic and oxidative insult \[[@B048]-[@B050]\]. CA is reported to have aldose reductase inhibitory activity \[[@B051]\]. Further, El-Bassossy *et al* (2011) reported that CA reduced hypertension associated with diabetes due to its having a direct protective effect on vascular function \[[@B016]\]. Thus, the anti-cataract activity shown by CA might be due, in addition to its antioxidant property, to its aldose reductase inhibitory action and the resulting protective effect on vascular function.

The fructose-fed rats developed hypertension and cataracts due to oxidative stress, as indicated by reductions in the levels of various antioxidant enzymes. Administration of CA reduced the SBP and the DBP due to its having protective effects on the vascular function, as well as antioxidant properties. CA may also inhibit the aldose reductase activity, the key enzyme in the polyol pathway responsible for cataractogenesis. Thus, we can conclude that CA attenuates cataractogenesis in fructose-fed hypertensive rats due to its having antihypertensive, anti-oxidant and aldose reductase inhibition activities.

![Effect of cinnamaldehyde on (a) the systolic blood pressure and (b) the diastolic blood pressure. Results are expressed as means ± SEMs, with n = 6. Data were analyzed by using the two-way ANOVA, followed by Bonferroni post tests. ^a^*P* \< 0.05, ^b^*P* \< 0.01, and ^c^*P* \< 0.001 as compared to day 0; ^d^*P* \< 0.05, ^e^*P* \< 0.01, ^f^*P* \< 0.001 as compared to week 3. CA-20 = cinnamaldehyde at 20 mg/kg/day; CA-30 = cinnamaldehyde at 30 mg/kg/day; CA-40 = cinnamaldehyde at 40 mg/kg/day.](2093-6966-v19-n02-137-g001){#F001}

![Photographs of lenses in the normal and the experimental groups: (A) normal, (B) control, (C) standard, and cinnamaldehyde at (D) 20 mg/kg/day (CA-20), (E) 30 mg/kg/day (CA-30), and (F) 40 mg/kg/day (CA-40).](2093-6966-v19-n02-137-g002){#F002}

###### Effect of cinnamaldehyde on GPx, CAT, SOD, GSH and MDA levels in serum

  Groups     GPx (μM/min/mg protein)   CAT (μM of H~2~O~2~ consumed/min/ mg protein)   SOD (μM/mg protein)   GSH (μM/mg protein)   MDA (μM/mg protein)
  ---------- ------------------------- ----------------------------------------------- --------------------- --------------------- ---------------------
  Normal     15.37 ± 0.39              0.63 ± 0.02                                     3.05 ± 0.20           2.88 ± 0.23           2.62 ± 0.12
  Control    5.11 ± 0.26^c^            0.33 ± 0.02^c^                                  1.08 ± 0.06^c^        1.33 ± 0.28^c^        3.5 ± 0.15^c^
  Standard   13.08 ± 0.35^cf^          0.53 ± 0.02^bf^                                 2.37 ± 0.08^af^       2.10 ± 0.18^ad^       2.55 ± 0.19^f^
  CA-20      11.27 ± 0.35^cfi^         0.44 ± 0.02^cfg^                                2.34 ± 0.10^af^       1.94 ± 0.08^bd^       2.78 ± 0.10^f^
  CA-30      13.36 ± 0.17^cf^          0.48 ± 0.02^cf^                                 2.69 ± 0.10^f^        2.38 ± 0.06^e^        2.11 ± 0.12^afg^
  CA-40      15.33 ± 0.21^fi^          0.64 ± 0.02^fh^                                 2.78 ± 0.29^f^        2.63 ± 0.18^f^        1.87 ± 0.11^bfh^

Values are expressed as means ± SEMs, with n = 6. Data were analyzed by using the one-way ANOVA, followed by the Newman-Keuls post test. ^a^*P* \< 0.05, ^b^*P* \< 0.01, and ^c^*P* \< 0.001 compared with the normal group, ^d^*P* \< 0.05, ^e^*P* \< 0.01, and ^f^*P* \< 0.001 compared with the control group, and ^g^*P* \< 0.05, ^h^*P* \< 0.01, ^i^*P* \< 0.001 compared with the standard group. CA-20 = cinnamaldehyde at 20 mg/kg/day; CA-30 = cinnamaldehyde at 30 mg/kg/day; CA-40 = cinnamaldehyde at 40 mg/kg/day. GPx, glutathione peroxidase; CAT, catalase; SOD, superoxide dismutase; GSH, glutathione; MDA, malonaldehyde; SEMs, standard errors of the mean; ANOVA, analysis of variance.

###### Effects of the cinnamaldehyde GPx, CAT, SOD, GSH and MDA levels in the lens

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group      GPx (μM/min/mg lens protein)   CAT (μM of H~2~O~2~ consumed/min/mg protein)   SOD (μM/mg lens\   GSH (μM/mg protein)   MDA (μM/mg lens protein)
                                                                                           protein)                                 
  ---------- ------------------------------ ---------------------------------------------- ------------------ --------------------- --------------------------
  Normal     8.24 ± 0.46                    0.46 ± 0.02                                    2.74± 0.05         2.51 ± 0.33           0.19 ± 0.02

  Control    2.16 ± 0.13^c^                 0.26 ± 0.01^c^                                 0.82 ± 0.02^c^     1.54 ± 0.09^b^        0.61 ± 0.02^c^

  Standard   4.97 ± 0.15^cf^                0.35 ± 0.02^e^                                 2.08 ± 0.22^f^     1.90 ± 0.01^a^        0.13 ± 0.02^f^

  CA-20      5.49 ± 0.43^cf^                0.40 ± 0.02^e^                                 1.52 ± 0.08^bd^    1.73 ± 0.06^b^        0.12 ± 0.01^f^

  CA-30      5.99 ± 0.08^cfg^               0.44 ± 0.03^f^                                 2.28 ± 0.36^f^     2.02 ± 0.03^d^        0.09 ± 0.02^af^

  CA-40      7.65 ± 0.02^fi^                0.52 ± 0.05^cfi^                               2.45 ± 0.20^f^     2.46 ± 0.01^eg^       0.06 ± 0.01^bf^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are expressed as means ± SEMs, with n = 6. Data were analyzed by using the one-way ANOVA, followed by the Newman-Keuls post test. ^a^*P* \< 0.05, ^b^*P* \< 0.01, and ^c^*P* \< 0.001 compared with the normal group, ^d^*P* \< 0.05, ^e^*P* \< 0.01, and ^f^*P* \< 0.001 compared with the control group, and ^g^*P* \< 0.05, ^h^*P* \< 0.01, and ^i^*P* \< 0.001 compared with the standard group. CA-20 = cinnamaldehyde at 20 mg/kg/day; CA-30 = cinnamaldehyde at 30 mg/kg/day; CA-40 = cinnamaldehyde at 40 mg/kg/day. GPx, glutathione peroxidase; CAT, catalase; SOD, superoxide dismutase; GSH, glutathione; MDA, malonaldehyde; SEMs, standard errors of the mean; ANOVA, analysis of variance.

###### Effect of cinnamaldehyde on the total protein and Ca^2+^ATPase levels in the lens

  Groups     TP (mg/mg lens tissue)   Ca^2+^ATPase (μM/min/mg inorganic phosphate)
  ---------- ------------------------ ----------------------------------------------
  Normal     0.70 ± 0.01              16.78 ± 0.39
  Control    0.27 ± 0.01^c^           11.28 ± 0.24^c^
  Standard   0.68 ± 0.03^f^           11.00 ± 0.20^c^
  CA-20      0.36 ± 0.04^ci^          11.96 ± 0.20^c^
  CA-30      0.40 ± 0.04^cdi^         12.90 ± 0.03^cfi^
  CA-40      0.68 ± 0.01^f^           15.19 ± 0.40^cfi^

Values are expressed as means ± SEMs, with n = 6. Data were analyzed by using the one-way ANOVA, followed by the Newman- Keuls post test. ^a^*P* \< 0.05, ^b^*P* \< 0.01, and ^c^*P* \< 0.001 compared with the normal group, ^d^*P* \< 0.05, ^e^*P* \< 0.01, and ^f^*P* \< 0.001 compared with the control group, and ^g^*P* \< 0.05, ^h^*P* \< 0.01, and ^i^*P* \< 0.001 compared with the standard group. CA-20 = cinnamaldehyde at 20 mg/kg/day; CA-30 = cinnamaldehyde at 30 mg/kg/day; CA-40 = cinnamaldehyde at 40 mg/kg/day. ATP, adenosine triphosphate; TP, total protein; SEMs, standard errors of the mean; ANOVA, analysis of variance.
